NASDAQ:KTRA Kintara Therapeutics (KTRA) Stock Forecast, Price & News $3.15 -0.32 (-9.22%) (As of 06/5/2023 ET) Add Compare Share Share Today's Range$3.13▼$3.3650-Day Range$2.77▼$4.3652-Week Range$2.70▼$20.00Volume17,475 shsAverage Volume22,259 shsMarket Capitalization$5.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Kintara Therapeutics (NASDAQ:KTRA) StockKintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.Read More Receive KTRA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kintara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KTRA Stock News HeadlinesMay 19, 2023 | finance.yahoo.comKintara Therapeutics to Commemorate National Brain Tumor Awareness Month with Ringing the Bell at Nasdaq Closing Along with Global Coalition for Adaptive Research and the National Brain Tumor SocietyMay 12, 2023 | msn.comRecap: Kintara Therapeutics Q3 EarningsJune 6, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.May 11, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2023 Third Quarter Financial Results and Provides Corporate UpdateMay 8, 2023 | finance.yahoo.comKintara Therapeutics to Present at the Sidoti Micro-Cap Virtual ConferenceMay 1, 2023 | finance.yahoo.comKintara Therapeutics to Present at the Aegis Capital Virtual ConferenceMay 1, 2023 | americanbankingnews.comKintara Therapeutics, Inc. (NASDAQ:KTRA) Short Interest Down 12.9% in AprilApril 14, 2023 | finance.yahoo.comKintara Therapeutics Announces Data Presentation at the 2023 American Association for Cancer Research Annual MeetingJune 6, 2023 | Edge On The Street (Ad)The Ignored EV Story Few Investors Know AboutLithium may grab all the headlines, but the average electric vehicle requires 146 pounds of the mineral graphite. With no producing graphite mines in North America, the U.S. government is desperate for more domestic sources of the metal to feed the EV battery supply chain.March 17, 2023 | ca.finance.yahoo.comThese 4 Biotech Stocks Just Got ‘Fast Track’ Designation GreenlightsMarch 15, 2023 | finance.yahoo.comKintara Therapeutics to Present Two Posters at the 2023 American Association for Cancer Research Annual MeetingMarch 10, 2023 | finance.yahoo.comKintara Therapeutics Scheduled to Present at Two Conferences the Week of March 13, 2023February 14, 2023 | finance.yahoo.comKintara Therapeutics Announces Fiscal 2023 Second Quarter Financial Results and Provides Corporate UpdateJanuary 30, 2023 | finance.yahoo.comKintara Therapeutics to Present at the 2023 BIO CEO & Investor ConferenceJanuary 9, 2023 | finance.yahoo.comKintara Therapeutics to Present at the Biotech Showcase Conference on January 10, 2023December 15, 2022 | marketwatch.comKintara Therapeutics Shares Rise 29% After Orphan Drug Designation for VAL-083December 15, 2022 | msn.comWhy Kintara Therapeutics Stock Is Seeing Blue Skies ThursdayDecember 15, 2022 | finance.yahoo.comKintara Therapeutics Receives Orphan Drug Designation for VAL-083 for Treatment of Diffuse Intrinsic Pontine Glioma (DIPG)December 2, 2022 | finance.yahoo.com10 Pump and Dump Stocks Hedge Funds LikeDecember 1, 2022 | baystreet.caLatest Set of FDA Fast Track Designations Causing Optimism in Biotech SectorDecember 1, 2022 | benzinga.comWave of FDA Fast Track Designations Sparks Renewed Interest in Biotech Sector That's Heating UpDecember 1, 2022 | finance.yahoo.comKintara Therapeutics to Participate at the RHK Capital Disruptive Growth Conference on December 5-6, 2022November 30, 2022 | msn.comAnalyzing Kintara Therapeutics's Short InterestNovember 30, 2022 | finance.yahoo.comKintara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementNovember 28, 2022 | markets.businessinsider.comKintara: FDA Grants Fast Track Designation To REM-001 Therapy - Quick FactsNovember 28, 2022 | markets.businessinsider.comKintara Therapeutics Rallies As Its REM-001 To Treat Breast Cancer Gets Fast Track DesignationNovember 28, 2022 | msn.comWhat's Going On With Kintara Therapeutics Stock?See More Headlines KTRA Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KTRA Company Calendar Last Earnings5/11/2023Today6/06/2023Fiscal Year End6/30/2023Next Earnings (Estimated)9/26/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KTRA CUSIPN/A CIK1498382 Webwww.kintara.com Phone(858) 350-4364Fax604-608-5685Employees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($11.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,660,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-146.35% Debt Debt-to-Equity RatioN/A Current Ratio2.16 Quick Ratio2.16 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.58) per share Price / Book-5.43Miscellaneous Outstanding Shares1,690,000Free Float1,619,000Market Cap$5.32 million OptionableNot Optionable Beta0.93 Key ExecutivesRobert E. HoffmanChairman, President & Chief Executive OfficerGreg A. JohnsonHead-OperationsScott PraillChief Financial Officer & SecretaryDennis M. BrownChief Scientific OfficerKey CompetitorsAdamis PharmaceuticalsNASDAQ:ADMPPainReformNASDAQ:PRFXHoth TherapeuticsNASDAQ:HOTHAllarity TherapeuticsNASDAQ:ALLRBiophytisNASDAQ:BPTSView All CompetitorsInstitutional OwnershipSusquehanna International Group LLPBought 10,662 shares on 5/16/2023Ownership: 0.630%View All Institutional Transactions KTRA Stock - Frequently Asked Questions Should I buy or sell Kintara Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Kintara Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" KTRA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KTRA, but not buy additional shares or sell existing shares. View KTRA analyst ratings or view top-rated stocks. How have KTRA shares performed in 2023? Kintara Therapeutics' stock was trading at $6.89 at the start of the year. Since then, KTRA stock has decreased by 54.3% and is now trading at $3.15. View the best growth stocks for 2023 here. When is Kintara Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, September 26th 2023. View our KTRA earnings forecast. How were Kintara Therapeutics' earnings last quarter? Kintara Therapeutics, Inc. (NASDAQ:KTRA) posted its earnings results on Thursday, May, 11th. The company reported ($1.94) EPS for the quarter, missing analysts' consensus estimates of ($0.10) by $1.84. When did Kintara Therapeutics' stock split? Kintara Therapeutics's stock reverse split on Monday, November 14th 2022. The 1-50 reverse split was announced on Monday, November 14th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, November 14th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. What other stocks do shareholders of Kintara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kintara Therapeutics investors own include Ampio Pharmaceuticals (AMPE), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Fortress Biotech (FBIO), Immunic (IMUX), Miragen Therapeutics (MGEN), Palatin Technologies (PTN), Rigel Pharmaceuticals (RIGL) and Trevena (TRVN). What is Kintara Therapeutics' stock symbol? Kintara Therapeutics trades on the NASDAQ under the ticker symbol "KTRA." Who are Kintara Therapeutics' major shareholders? Kintara Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Susquehanna International Group LLP (0.63%). Insiders that own company stock include Anthony Scott Praill, Laura L Johnson and Saiid Zarrabian. View institutional ownership trends. How do I buy shares of Kintara Therapeutics? Shares of KTRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Kintara Therapeutics' stock price today? One share of KTRA stock can currently be purchased for approximately $3.15. How much money does Kintara Therapeutics make? Kintara Therapeutics (NASDAQ:KTRA) has a market capitalization of $5.32 million. The company earns $-22,660,000.00 in net income (profit) each year or ($11.04) on an earnings per share basis. How can I contact Kintara Therapeutics? Kintara Therapeutics' mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The official website for the company is www.kintara.com. The company can be reached via phone at (858) 350-4364, via email at ir@delmarpharma.com, or via fax at 604-608-5685. This page (NASDAQ:KTRA) was last updated on 6/6/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kintara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.